Log In
Print this Print this

CYPC9*2 & *3 Test

  Manage Alerts
Collapse Summary General Information
Company PharmiGene Inc.
DescriptionDNA genetic detection test to predict warfarin dosage
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCardiovascular, Diagnostic
Indication DetailsAsses warfarin dosage requirements based on CYP2C9 genotypes
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today